Stock Market & Financial Investment News

News Breaks January 9, 2013 07:33 EDT VSTM, LH Verastem and LabCorp partner to validate biomarker for cancer Verastem (VSTM) entered an agreement with LabCorp (LH) to validate biomarkers for its lead focal adhesion kinase inhibitor VS-6063 in the development of an applicable companion diagnostic. The biomarkers will be the subject of clinical studies in ovarian cancer and mesothelioma, including a potentially pivotal study of VS-6063 in mesothelioma expected to initiate later this year. News For VSTM;LH From The Last 14 Days Check below for free stories on VSTM;LH the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 22, 2013 10:14 EDT VSTM Verastem management to meet with Guggenheim Meetings to be held on the West Coast May 23-24 hosted by Guggenheim. 07:28 EDT VSTM UBS to host a conference Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link May 21, 2013 07:44 EDT VSTM Sachs Associates to host a forum Subscribe for More Information May 14, 2013 07:04 EDT VSTM Verastem appoints Jack Green as CFO Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.